Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

Publication ,  Journal Article
Crout, CA; Koh, L-P; Gockerman, JP; Moore, JO; Decastro, C; Long, GD; Diehl, L; Gasparetto, C; Niedzwiecki, D; Edwards, J; Prosnitz, L ...
Published in: Cancer Invest
July 2010

We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a high preponderance of genetic alterations conferring resistance to standard chemotherapy in this illness. Concurrent with this investigation, we present a series of patients who were provided dose-dense and intense chemotherapy to circumvent these drug-resistance mechanisms. High responses were noted, though durable remissions were few, indicating non-traditional chemotherapy options are important to investigate in this illness.

Duke Scholars

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

July 2010

Volume

28

Issue

6

Start / End Page

654 / 660

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Polymorphism, Genetic
  • Peripheral Blood Stem Cell Transplantation
  • Oncology & Carcinogenesis
  • Mitoxantrone
  • Middle Aged
  • Male
  • Lymphoma, Mantle-Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crout, C. A., Koh, L.-P., Gockerman, J. P., Moore, J. O., Decastro, C., Long, G. D., … Rizzieri, D. A. (2010). Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. Cancer Invest, 28(6), 654–660. https://doi.org/10.3109/07357901003631015
Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
Crout CA, Koh L-P, Gockerman JP, Moore JO, Decastro C, Long GD, et al. Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. Cancer Invest. 2010 Jul;28(6):654–60.
Crout, Christopher A., et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.Cancer Invest, vol. 28, no. 6, July 2010, pp. 654–60. Pubmed, doi:10.3109/07357901003631015.
Crout CA, Koh L-P, Gockerman JP, Moore JO, Decastro C, Long GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA. Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. Cancer Invest. 2010 Jul;28(6):654–660.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

July 2010

Volume

28

Issue

6

Start / End Page

654 / 660

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Polymorphism, Genetic
  • Peripheral Blood Stem Cell Transplantation
  • Oncology & Carcinogenesis
  • Mitoxantrone
  • Middle Aged
  • Male
  • Lymphoma, Mantle-Cell